Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
TECH Catalyst Timeline
Dated clinical, regulatory and corporate events for Bio-Techne Corp
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bio-Techne Corp
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How TECH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every TECH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| metastatic melanoma | 2025-11-04 | 42 pre-treatment biopsies, three treatment arms incorporating Immune Checkpoint Blockade (ICB)Read More | AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma PatientsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hippel JamesOfficer (CFO) | Option | 11,545 181,816 held | $0.00 | 11/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TECH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| IRON TRIANGLE PARTNERS LP | 3.1 % (34.8 %) | 27.49 M | 467.41 K | 86.96% ( 217.41 K) |
Ownership Trends
TECH Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How TECH ranks across every disease it competes in
TECH News
BIO-TECHNE DECLARES DIVIDEND
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for Q3 2026. The dividend is payable on November 23, 2026, to shareholders recorded by November 13, 2026. This decision is contingent upon the completion of Bio-Techne's acquisition by Merck KGaA. Future dividends will be evaluated quarterly by the Board.
Read more →Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
Bio-Techne has opened a new GMP manufacturing facility in Bristol, UK, to enhance its capabilities in supporting the cell therapy market. This 10,000-square-foot facility features advanced cleanrooms designed for high-quality small molecule production. The investment aims to address manufacturing challenges in cell therapy, ensuring consistent and scalable processes for therapy developers.
Read more →Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Bio-Techne shareholders have approved the acquisition by Merck KGaA, marking a significant step towards completing the merger. The transaction is expected to provide substantial cash value to shareholders and enhance the capabilities of both companies in life sciences. The acquisition is anticipated to close by late 2026 or early 2027, pending regulatory approvals.
Read more →Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne has inaugurated a new Customer Experience Center in Düsseldorf, Germany, aimed at enhancing collaboration and innovation in the life sciences sector. This facility will serve as a regional hub for researchers and organizations in the DACH and EMEA regions, providing hands-on access to Bio-Techne's technologies and expertise. The center will host workshops and training programs, reinforcing Bio-Techne's commitment to supporting scientific excellence across Europe.
Read more →Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Bio-Techne Corporation has made significant strides in its climate goals, achieving validation from the Science Based Targets initiative for its greenhouse gas reduction targets. The company reported a 49% reduction in Scope 1 and 2 emissions year-over-year and transitioned to 100% renewable electricity at its Minneapolis headquarters. Additionally, Bio-Techne aims for 81% of its suppliers to have science-based targets by fiscal year 2030.
Read more →Bio-Techne Corrects Dividend Announcement
Bio-Techne Corporation corrected its dividend announcement, stating the shareholder of record date is August 24, 2026, instead of August 17. The company will pay a dividend of $0.08 per share for the quarter ended June 30, 2026, payable on August 28, 2026. All other details of the announcement remain unchanged.
Read more →Bio-Techne Declares Dividend
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for shareholders of record on August 17, 2026. This dividend reflects the company's strong financial performance, having generated over $1.2 billion in net sales in fiscal year 2026. The company, celebrating its 50th anniversary, continues to empower scientific communities globally.
Read more →Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
Bio-Techne Corporation reported its financial results for the fourth quarter of fiscal 2026, highlighting a 3% increase in organic revenue and a significant improvement in GAAP EPS. The company is set to be acquired by Merck KGaA for $73 per share, which is anticipated to provide new opportunities for growth. Despite these positives, adjusted EPS saw a slight decline, and overall revenue remained flat for the year.
Read more →Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
Bio-Techne Corporation has expanded its R&D Systems AI-Engineered Designer Protein portfolio with new heat-stable and hyperactive proteins. These innovations aim to enhance reproducibility and performance in advanced cell culture and cell therapy workflows. The new proteins are designed to address challenges in scaling cell therapy from discovery to manufacturing, supporting various applications in regenerative medicine.
Read more →Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Merck KGaA has agreed to acquire Bio-Techne for $73 per share, totaling $11.3 billion. This acquisition aims to enhance Merck's leadership in life sciences by integrating Bio-Techne's advanced technologies. The deal is expected to be accretive to sales growth and EBITDA margins, with significant cost synergies projected by year three.
Read more →Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
Bio-Techne and Refeyn announced an integrated workflow for characterizing bispecific antibodies and biosimilars. The system combines icIEF fractionation with mass photometry to analyze charge and size variants. This method completes analysis in four hours using only nanogram-level samples. The approach aims to reduce development risk and accelerate manufacturing processes.
Read more →Bio-Techne Releases Third Quarter Fiscal 2026 Results
Bio-Techne Corporation reported its third quarter fiscal 2026 results, revealing a 2% decline in revenue to $311.4 million, impacted by prior-year orders and shipment timing. Despite this, GAAP EPS rose to $0.32, and large pharma continued its growth trend. The company remains optimistic about future demand as funding activity stabilizes.
Read more →Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference
Bio-Techne Corporation announced that CEO Kim Kelderman will present at the Bank of America Securities 2026 Global Healthcare Conference on May 12, 2026. The presentation will be accessible via a live webcast on the company's Investor Relations website. Bio-Techne has a rich history of 50 years in the life sciences sector and operates globally.
Read more →Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
Bio-Techne Corporation has introduced a streamlined brand architecture to improve customer navigation of its life science solutions. The new structure organizes products into three focused brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, aligning with the progression of scientific research. This initiative aims to empower scientists and clinicians by providing easier access to essential tools and technologies.
Read more →Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
Bio-Techne Corporation announced a conference call scheduled for May 6, 2026, to discuss its third quarter fiscal 2026 financial results. The call will be accessible via dial-in and webcast, with a replay available for those unable to attend live. The company continues to thrive in the life sciences sector, generating significant revenue.
Read more →Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
Bio-Techne Corporation has expanded its COMET solution portfolio by introducing SPYRE Focus Panels and SPYRE Amplification Kits. These innovations aim to enhance the modular, automated spatial biology workflow, providing researchers with greater flexibility and sensitivity. The new features in HORIZON Image Analysis Software further support these advancements, facilitating deeper biological insights from tissue samples.
Read more →Bio-Techne to Present at Upcoming Investor Conferences
Bio-Techne Corporation has announced its participation in two upcoming investor conferences. The TD Cowen 46th Annual Health Care Conference is scheduled for March 3, 2026, and the Leerink Partners Global Healthcare Conference will take place on March 10, 2026. Live webcasts of these presentations will be available on the company's Investor Relations website.
Read more →Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
Bio-Techne Corporation's Ella platform has received CE-IVD marking, allowing its sale in the European Union. This compact, cartridge-based immunoassay system provides rapid and accurate biomarker results, enhancing clinical workflows. The certification enables European laboratories to utilize Ella for in-house test development and clinical trials, supporting precision medicine initiatives.
Read more →Bio-Techne Announces Changes to its Leadership Team
Bio-Techne Corporation announced a leadership change, with Dr. Matt McManus transitioning from his role as President of the Diagnostics and Spatial Biology Segment effective March 1, 2026. Steve Crouse, previously Senior Vice President of the Analytical Solutions Division, will take over as President. The transition aims to ensure continuity and leverage Crouse's extensive experience in the life sciences sector.
Read more →